On May 27, Insilico Medicine and Human Life Foundation Models, a newly established company under Human Longevity, announced a multi-million-dollar strategic partnership. The two parties will jointly develop the first large-scale AI foundational model for human longevity science research. By integrating advanced algorithms with deep biological insights, the model is expected to be commercialized and drive breakthroughs in various aspects, including early detection of age-related diseases, predictive health risk modeling, AI-driven longevity drug development, and personalized interventions.
